We’re for those who want to suppress VEGF for longer
Mode of action
EYLEA is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (AMD) and visual impairment due to diabetic macular oedema (DME).
Unleash the power of aflibercept with EYLEA 8mg, a 4x higher molar dose of the tried-and-trusted EYLEA 2mg
- A higher dose results in an effective concentration for longer in the eye
Aflibercept mode of action
Learn the rationale behind testing a higher molar dose
- Abbreviationsexpand_more
DME: diabetic macular oedema.
Fc: fragment crystallisable.
IgG: immunoglobulin G.
nAMD: neovascular (wet) age-related macular degeneration.
PlGF: placental growth factor.
q8: every 8 weeks.
VEGF: vascular endothelial growth factor.
VEGFR: vascular endothelial growth factor receptor.
- Referencesexpand_less
- 1EYLEA® 8mg (aflibercept 114.3 mg/mL, solution for injection) Summary of Product Characteristics. Berlin, Germany: Bayer Pharma AG.
- 2Do DV, et al. Retina 2020;40:643–647.
- 3Papadopoulos N, et al. Angiogenesis 2012;15:171–185.
- 4Veritti D, et al. Pharmaceutics 2023;15:1416.
- 5Korobelnik J-F. Intravitreal aflibercept 8 mg injection in patients with neovascular age-related macular degeneration: 48-Week results from the Phase 3 PULSAR trial. Retina Society 55th Annual Scientific Meeting. 2–5 November 2022. Pasadena, USA. Oral presentation.
- 6Do D. Aflibercept 8 mg for diabetic macular edema: 48-week results from the Phase 2/3 PHOTON trial. Association for Research in Vision and Ophthalmology 2023 Meeting. 23–27 April 2023. Palo Alto, USA. Oral presentation.
- Footnotesexpand_less
- aEYLEA (aflibercept) 2mg was dosed at fixed q8 intervals after 3 (nAMD) or 5 (DME) initial monthly injections.⁵،⁶
- bBased on mathematical modelling.⁴